Labcorp Buys BioReference as Insiders Sell and Debt Mounts
Labcorp is acquiring BioReference Health assets for up to $872 million while carrying $5.9 billion in debt and just $142 million in cash, with quarterly free cash flow down 42% year-over-year. The com
Labcorp to Buy BioReference Assets for Up to $872M
NEW YORK, October 17 —
Labcorp Holdings Inc. (LH) is pressing forward with an $872 million acquisition of BioReference Health assets while carrying just $142 million in cash against $5.9 billion in debt, with quarterly free cash flow already 42% below last year's level. The question is not whether management has ambition; it's whether the balance sheet can absorb it.
- Q2 free cash flow fell to $314M from $543M a year earlier; Labcorp carries $5.9B in total debt.
- Q2 adjusted EPS of $4.99 beat consensus by $0.22; full-year EPS guidance raised to $18.10, $18.55.
- Five insiders sold $3.17M in open-market shares in August; zero purchases over 90 days.
Thin Cash, Big Check
Labcorp operates two segments: a Diagnostics business built on blood chemistry, oncology screens, PAP tests, and women's health services that generated $2.9 billion in Q2 2026 revenue, and a BLS arm serving pharma clients through clinical trials and early development work, generating $836 million. The BioReference acquisition extends the Diagnostics footprint, a logical move for a lab network seeking scale. What complicates the picture is the spending pattern surrounding the deal: in Q2, Labcorp retired $500 million in senior notes, deployed $226 million in acquisitions, and repurchased $354 million in shares, all while FCF fell to $314 million. Adding $872 million more onto that posture is a significant commitment.
Five Sellers, Zero Buyers
The insider activity over the same period adds a cautionary layer. Per Form 4 filings, CEO Adam Schechter sold 4,669 shares at $320.37 on August 11 and director Kerrii B. Anderson sold 3,000 at $318.02 on August 17. Five insiders in total, including the Chief Marketing Officer and Chief Accounting Officer, offloaded $3.17 million in open-market shares over 90 days with zero purchases logged. Labcorp trades at $317.95 today, meaning those sellers reduced their exposure at prices nearly identical to current levels while the company arranged a near-$900 million commitment. Five sellers, no buyers: the direction is clear.
| Ticker | Mkt cap | Fwd P/E | 52-wk |
|---|---|---|---|
| LH | $25.8B | 16.0x | +11.7% |
| DGX | $25.9B | 19.5x | +25.6% |
| WAT | $42.9B | 26.4x | +29.4% |
| UHS | $10.9B | 7.7x | -9.6% |
| IQV | $43.9B | 18.5x | +32.5% |
| MTD | $32.5B | 31.3x | +20.8% |
What Q3 Will Settle
The counterargument is real: Labcorp has delivered four consecutive EPS beats, and management raised full-year adjusted EPS guidance to $18.10, $18.55 while maintaining full-year free cash flow guidance at $1.24, $1.36 billion, suggesting Q2's decline was timing-related rather than structural. Its BLS backlog of $8.7 billion carries $2.7 billion expected to convert in the next 12 months; the book-to-bill ratio of 1.14 points to continued demand. At a 16.1x forward P/E against a consensus target of $345.13, the upside exists if execution holds. The number to watch: if full-year FCF lands above $1.24 billion, the BioReference deal is defensible; if not, the leverage math tightens considerably.
Run the free Labcorp Holdings Inc. deep-dive →
Basis Report is independent research for informational purposes. It is not investment advice and not a recommendation to buy or sell any security.
Frequently Asked Questions
How much is Labcorp paying for BioReference?
Labcorp is acquiring BioReference Health assets for up to $872 million. This move extends the company's Diagnostics segment, which generated $2.9 billion in Q2 2026 revenue.
Why are Labcorp insiders selling shares?
Five insiders, including CEO Adam Schechter and director Kerrii B. Anderson, sold a combined $3.17 million in shares during August at prices near current levels, while zero executives made purchases over the same 90-day period. This pattern suggests insiders are reducing their exposure as the company commits to a major acquisition.
What is Labcorp's debt and cash position?
Labcorp carries $5.9 billion in total debt against just $142 million in cash. In Q2, free cash flow fell to $314 million from $543 million a year earlier, even as the company spent $500 million retiring senior notes and $354 million repurchasing shares.
Did Labcorp beat Q2 earnings expectations?
Yes. Q2 adjusted EPS of $4.99 beat consensus by $0.22, marking the fourth consecutive EPS beat. Management raised full-year adjusted EPS guidance to $18.10, $18.55.
What free cash flow target matters for the deal?
Labcorp maintained full-year free cash flow guidance at $1.24, $1.36 billion. If full-year FCF lands above $1.24 billion, the acquisition is defensible; if it falls short, the company's leverage position tightens considerably.
Labcorp Holdings announced an agreement to acquire select assets of OPKO Health's BioReference Health unit for up to $872 million — a major diagnostics expansion. The announcement lands while Labcorp carries $5.9 billion in total debt against only $142 million in cash after Q2 free cash flow dropped 42% year over year.